HotSpot Therapeutics Appoints Niti Goel, M.D., as Chief Medical Officer
Seasoned drug development leader to drive clinical development of small molecule IRF5 inhibitor, HST-2011, nominated as Development Candidate for lupus and other autoimmune diseases BOSTON, Aug. 18, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.